We built Prospectio, which is first on this list. The other five entries are written as fairly as we can manage.
1. Prospectio
Reads every profile against your ICP before sending, skips poor fits, sends cloned voice and video personalised per prospect, and uses an AI responder to reply and book the meeting. Residential IP per account, mobile-style API. $99 per seat per month, annual. The difference from Expandi is the message itself: a human voice instead of a personalised image, and qualification instead of sending to everyone. Full comparison.
2. Dripify
A simpler, cheaper cloud sequencing tool. Clean interface, reliable, team features, A/B testing. Text-only and no qualification, so the reply-rate ceiling is the same as Expandi’s, at a lower price. From roughly $39 per month on the entry plan at time of writing. Prospectio vs Dripify.
3. HeyReach
Built for agencies: unlimited LinkedIn accounts on agency plans, one inbox, per-account pricing, API and MCP, deep integrations with Clay, Make and n8n. If you’re an agency comparing Expandi’s whitelabel against HeyReach, HeyReach’s account-scale model usually wins. Prospectio vs HeyReach.
4. Waalaxy
Freemium, simple, browser-extension based. The free tier is limited but real. Good for a solo founder testing whether LinkedIn outbound works for them at all. Not a team tool.
5. Lemlist
Email-first with LinkedIn steps, strong deliverability tooling, large template library, personalised images and landing pages. If most of your sequence is email, Lemlist is a better centre of gravity than any LinkedIn-first tool.
6. Skylead
Cloud-based, smart sequences with conditions, image and GIF personalisation, email discovery built in. The closest like-for-like to Expandi in feature shape. Worth a demo if you like Expandi’s approach and want to compare pricing and interface.
Choosing
Decide what you’re optimising for. Cheaper sends: Dripify or Waalaxy. More accounts: HeyReach. Email-led: Lemlist. Same shape, different vendor: Skylead. Higher reply rate and booked meetings from the same list: Prospectio.